APA (7th ed.) Citation

T, A., T, S., S, G., B, Z., D, B., E, N., . . . B, R. (2026). Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study. Kidney medicine, 8(7), 101394. https://doi.org/10.1016/j.xkme.2026.101394

Chicago Style (17th ed.) Citation

T, Agur, Steinmetz T, Goldman S, Zingerman B, Bielopolski D, Nesher E, Fattal I, Meisel E, and Rozen-Zvi B. "Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study." Kidney Medicine 8, no. 7 (2026): 101394. https://doi.org/10.1016/j.xkme.2026.101394.

MLA (9th ed.) Citation

T, Agur, et al. "Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study." Kidney Medicine, vol. 8, no. 7, 2026, p. 101394, https://doi.org/10.1016/j.xkme.2026.101394.